Characterization of iopromide liposomes
- PMID: 8276573
- DOI: 10.1097/00004424-199311000-00011
Characterization of iopromide liposomes
Abstract
Rationale and objectives: Iopromide-carrying liposomes were prepared and were characterized pharmaceutically and biologically.
Methods: The liposomes were prepared by the ethanol evaporation method and were characterized by quasi-elastic light scattering (size) and equilibrium dialysis (encapsulation efficiency and stability). Acute and subchronic toxicity was tested in mice and/or rats and cardiovascular tolerance in rabbits. Pharmacokinetic parameters were determined in rats. Computed tomography (CT) imaging efficiency was obtained from rat and rabbit studies.
Results: The mean diameter was 0.5 +/- 0.1 micron and the encapsulation efficiency ranged between 30% and 40%. The liposomes were stable in human and rabbit plasma for approximately 24 hours. The LD50 in mouse and rat was approximately 3 g iodine/kg. In a subchronic toxicity study in rats with six doses of 1 g iodine/kg given every three days, no adverse effects were observed. The pharmacokinetics in rats were dose-dependent. Increasing the dose resulted in lower total clearance, and longer terminal half-life. Elimination of iodine was complete and the main route of excretion was via the kidneys. A clinically relevant computed tomography enhancement of the liver was reached after approximately 200 mg iodine/kg in rats and 150 mg iodine/kg in rabbits.
Conclusions: The iopromide-carrying liposomes were well tolerated in animal studies and seemed to be suitable for the imaging of the liver.
Similar articles
-
An overview of the clinical pharmacokinetics of x-ray contrast media.Clin Pharmacokinet. 1997 Mar;32(3):180-93. doi: 10.2165/00003088-199732030-00002. Clin Pharmacokinet. 1997. PMID: 9084958 Review.
-
Characterization of continuously extruded iopromide-carrying liposomes for computed tomography blood-pool imaging.Invest Radiol. 2001 Jun;36(6):303-8. doi: 10.1097/00004424-200106000-00001. Invest Radiol. 2001. PMID: 11410749
-
Preparation and evaluation of lyophilized iopromide-carrying liposomes for liver tumor detection.Invest Radiol. 1993 Sep;28(9):838-44. Invest Radiol. 1993. PMID: 8225891
-
CT imaging with iopromide liposomes in a rabbit model.J Liposome Res. 2011 Sep;21(3):229-36. doi: 10.3109/08982104.2010.527852. Epub 2010 Nov 2. J Liposome Res. 2011. PMID: 21039317
-
Preclinical characterization of iopromide.Invest Radiol. 1994 May;29 Suppl 1:S21-32. doi: 10.1097/00004424-199405001-00005. Invest Radiol. 1994. PMID: 8071040 Review. No abstract available.
Cited by
-
An overview of the clinical pharmacokinetics of x-ray contrast media.Clin Pharmacokinet. 1997 Mar;32(3):180-93. doi: 10.2165/00003088-199732030-00002. Clin Pharmacokinet. 1997. PMID: 9084958 Review.
-
Bismuth@US-tubes as a Potential Contrast Agent for X-ray Imaging Applications.J Mater Chem B. 2013 Oct 7;1(37):10.1039/C3TB20742K. doi: 10.1039/C3TB20742K. J Mater Chem B. 2013. PMID: 24288589 Free PMC article.
-
Liposomes coloaded with iopamidol/lipiodol as a RES-targeted contrast agent for computed tomography imaging.Pharm Res. 2010 Jul;27(7):1408-15. doi: 10.1007/s11095-010-0135-5. Epub 2010 Apr 28. Pharm Res. 2010. PMID: 20424895
-
Preclinical Models of Brain Metastases in Breast Cancer.Biomedicines. 2022 Mar 13;10(3):667. doi: 10.3390/biomedicines10030667. Biomedicines. 2022. PMID: 35327469 Free PMC article. Review.
-
Nanoparticles for imaging: top or flop?Radiology. 2014 Oct;273(1):10-28. doi: 10.1148/radiol.14131520. Radiology. 2014. PMID: 25247562 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources